Amyris v. Lavvan CA1/2

CourtCalifornia Court of Appeal
DecidedMay 23, 2023
DocketA165829
StatusUnpublished

This text of Amyris v. Lavvan CA1/2 (Amyris v. Lavvan CA1/2) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Amyris v. Lavvan CA1/2, (Cal. Ct. App. 2023).

Opinion

Filed 5/23/23 Amyris v. Lavvan CA1/2 NOT TO BE PUBLISHED IN OFFICIAL REPORTS California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

FIRST APPELLATE DISTRICT

DIVISION TWO

AMYRIS, INC., Plaintiff and Appellant, A165829 v. LAVVAN, INC. et al., (Alameda County Super. Ct. No. Defendants and Respondents. 22CV008391)

In 2019, Amyris, Inc. (Amyris), a California corporation, entered into an agreement with Lavvan, Inc. (Lavvan), a Delaware corporation, to biosynthetically develop chemicals found in cannabis for commercial use—a project that, had it been successful, reportedly would have yielded hundreds of millions of dollars. It was not successful, and in 2020 Lavvan filed suit in the Southern District of New York, alleging breach of contract and infringement of its intellectual property, seeking over $880 million in damages, a lawsuit that proceeds to this day. Meanwhile, Amyris filed suit in Alameda County, alleging it had discovered that Lavvan officers and employees had recorded eight calls and meetings between the parties, in violation of the California Invasion of Privacy Act (Pen. Code, § 630 et seq.), and seeking the $5,000 statutory penalty for each of the eight recordings. Lavvan moved to transfer the case to

1 New York pursuant to a forum selection clause that “[a]ny dispute arising out of this Agreement shall be submitted exclusively” to that state. The trial court granted the motion, and Amyris appeals, asserting that: (1) the forum selection clause is inapplicable to its claim, and (2) enforcement of the forum selection clause would foreclose any justice for Amyris. We affirm. BACKGROUND The Parties and Their Relationship Plaintiff and appellant Amyris is a publicly held synthetic biology company, headquartered in Emeryville, California. Defendant and respondent Lavvan is a Delaware corporation, with its principal place of business in New York. In March 2019 Amyris and Lavvan entered into a research, collaboration, and license agreement to biosynthetically develop chemicals found in cannabis plants, known as cannabinoids, for commercial use (RCL Agreement), an extensive 49-page agreement describing the project in great detail. As pertinent here, the RCL Agreement had a forum selection clause and a choice of law provision that said, “This Agreement shall be construed in accordance with, and governed by, the laws of the State of New York, without regard to the conflicts of law provisions thereof. . . . Any dispute arising out of this Agreement shall be submitted exclusively to any state or Federal court located in New York County, New York, without restricting any rights of appeal.” Problems arose, and in September 2020 Lavvan filed suit in the United States District Court, Southern District of New York: Lavvan, Inc. v. Amyris, Inc. (S.D.N.Y, Sep. 10, 2020, No. 20-cv-07386-JPO) 2021 WL 3173054 (the New York lawsuit). The New York lawsuit alleged breach of the RCL

2 Agreement and infringement on Lavvan’s intellectual property rights, and sought over $880 million in damages. The complaint in the New York lawsuit began with a quote attributed to Amyris CEO John Melo, the introduction beginning as follows: “I. Introduction “Not one partner has ever stood with us and said, We’re only going to do what the contract says. . . . if that ever happened, we would be out of business today . . . .” The introduction continued with these five paragraphs: “1. This case seeks to remedy the predictable consequences that stem from a business partner’s view that it need not concern itself with the terms of the agreement it entered, and from that partner’s deliberate decision to misappropriate valuable intellectual property entrusted to it under that agreement for its own gain. “2. In 2019, Amyris addressed its short-term woes by publicly announcing that it would be entering a new industry by forming a promising exclusive partnership with Lavvan and securing from Lavvan a much-needed multi-million-dollar cash influx. Amyris then quickly proceeded to denounce the deal’s terms privately and to try to change and frustrate—and ultimately breach—those terms, all at the expense of Lavvan and its investors. In fact, Amyris has rejected the agreement’s most fundamental terms so thoroughly that Amyris evidently never meant to honor the contract at all. In the course of repudiating the agreement, Amyris misappropriated Lavvan’s trade secrets and used intellectual property licensed exclusively to Lavvan to compete against, rather than collaborate with, its supposed partner. “3. Amyris apparently saw the contract as a short-term fix for its deep and dire financial troubles—as Amyris’s CEO would come to describe it,

3 the deal was a decision for Amyris to ‘cut off its arm to save its body.’ The news of Amyris’s potentially lucrative partnership with Lavvan, in a rapidly growing and extremely attractive industry (biosynthetic cannabinoids), would stave off investors’ worries about the company’s hundreds of millions of dollars in losses, crushing debt load, and languishing stock price. But to get the deal it wanted to announce, Amyris had to agree to give Lavvan exclusive rights to valuable intellectual property, as well as control over decision about how and when the partnership would commercialize its collaborative research and development. “4. As Lavvan came to learn, ceding such control threatens to expose the rotten core of Amyris’s business, which has long depended on accounting schemes designed to hide massive manufacturing losses Amyris quietly absorbs in the development of its products. These schemes allow Amyris to portray itself as a leading player in the field of biotechnology, even while its financials tell a very different story of a company that cannot seem to turn a profit. “5. Accordingly, after having secured the benefits of Lavvan’s upfront $10 million payment and the positive stock-market effects of announcing its partnership, Amyris now hopes to ignore its contractual obligations, seize for itself Lavvan’s rights, and usurp for itself all of the benefits of the partnership—in flagrant violation of Lavvan’s intellectual property rights and the Parties’ operative agreement.” The complaint in the New York lawsuit went on to allege several specific conversations and meetings it claimed supported its position, including these three: (1) On February 23, 2020, Amyris’s CEO Melo informed Neil Closner, Lavvan’s CEO, that the Amyris board was looking for a way out of

4 the binding deal Amyris entered with Lavvan, and that one of Amyris’s options was for it to simply proceed to commercialize cannabinoids without Lavvan, in violation of the RCL Agreement. Melo threatened that unless Lavvan would agree to change the deal and accept whatever new terms Amyris demanded, Amyris would commercialize cannabinoids on its own and leave Lavvan behind. In short, that Amyris threatened to take Lavvan’s intellectual property and use it for Amyris’s own purposes unless Lavvan acceded to Amyris’s demands. (2) An April 6, 2020 conversation in which Closner objected to Melo’s demands that Lavvan make or sign contradictory statements for Amyris, one representing that Amyris was working to develop the controlled substance THC and one representing it was not. (3) An April 14, 2020 meeting at which Melo told Lavvan that Amyris would breach the parties’ agreement if Lavvan did not accede to Amyris’s demands about the timing of the manufacturing and commercialization process. As confirmed at oral argument, the New York lawsuit proceeds. Meanwhile, Amyris filed the lawsuit that led to the appeal here.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sargon Enterprises, Inc. v. University of Southern California
288 P.3d 1237 (California Supreme Court, 2012)
Smith, Valentino & Smith, Inc. v. Superior Court
551 P.2d 1206 (California Supreme Court, 1976)
Ribas v. Clark
696 P.2d 637 (California Supreme Court, 1985)
State Farm Mutual Automobile Insurance v. Partridge
514 P.2d 123 (California Supreme Court, 1973)
Stangvik v. Shiley Inc.
819 P.2d 14 (California Supreme Court, 1991)
Lewsadder v. Mitchum, Jones & Templeton, Inc.
36 Cal. App. 3d 255 (California Court of Appeal, 1973)
Khan v. Shiley Inc.
217 Cal. App. 3d 848 (California Court of Appeal, 1990)
Berman v. Dean Witter & Co., Inc.
44 Cal. App. 3d 999 (California Court of Appeal, 1975)
Furda v. Superior Court
161 Cal. App. 3d 418 (California Court of Appeal, 1984)
Damian v. Tamondong
77 Cal. Rptr. 2d 262 (California Court of Appeal, 1998)
Davis v. Farmers Ins. Group
35 Cal. Rptr. 3d 738 (California Court of Appeal, 2005)
Olinick v. BMG ENTERTAINMENT
42 Cal. Rptr. 3d 268 (California Court of Appeal, 2006)
Efund Capital Partners v. Pless
59 Cal. Rptr. 3d 340 (California Court of Appeal, 2007)
America Online, Inc. v. Superior Court
108 Cal. Rptr. 2d 699 (California Court of Appeal, 2001)
Johnson v. Siegel
101 Cal. Rptr. 2d 412 (California Court of Appeal, 2000)
Cal-State Business Products & Services, Inc. v. Ricoh
12 Cal. App. 4th 1666 (California Court of Appeal, 1993)
INTERSHOP COMMUNICATIONS, AG v. Superior Court
127 Cal. Rptr. 2d 847 (California Court of Appeal, 2002)
Net2Phone, Inc. v. Superior Court
135 Cal. Rptr. 2d 149 (California Court of Appeal, 2003)
Lerner v. Ward
13 Cal. App. 4th 155 (California Court of Appeal, 1993)
Xuereb v. Marcus & Millichap, Inc.
3 Cal. App. 4th 1338 (California Court of Appeal, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
Amyris v. Lavvan CA1/2, Counsel Stack Legal Research, https://law.counselstack.com/opinion/amyris-v-lavvan-ca12-calctapp-2023.